The combination of DSF, which reduces the protumor activity of macrophages, can significantly increase the number of cytotoxic CD8+ T cells in tumor cells when combined with PD-1 antibodies, enhancing the antitumor immune response and synergistically inhibiting the growth and metastasis of tumor cells. Here, PDCD1 is linked to neoplasm.